Board of directors

Joakim Söderström

Chairman of the board since 2022

Joakim Söderström, born 1984, is a successful entrepreneur and investor with a focus on biotech. His previous roles include CEO of SäkerhetsBranschen, Vice President of Euralarm and several different senior positions in the Swedish Police Authority.

Other ongoing assignments: Board member and Chief Executive Officer of J-TAC AB.

Holdings: Joakim Söderström holds 2 700 000 shares, both directly and indirectly, in Idogen AB.

Joakim Söderström is deemed to be independent in relation to both the company and its management, as well as to the major shareholders.

Niklas Wallet

Member of the board since 2022

Niklas Wallett, born 1976, has extensive experience as a professional investor and a broad network in the financial market. He has worked at institutions including Erik Penser Bank and Handelsbanken in various roles, with a focus on the capital market.

Other ongoing assignments: Board member of Wallett & Jefferyd AB.

Holdings: Niklas Wallett holds 2 431 333 shares, both directly and indirectly (including via family), in Idogen AB.

Niklas Wallett is deemed to be independent in relation to both the company and its management, as well as to the major shareholders.

Agneta Edberg

Member of the board since 2016

Agneta Edberg has over 20 years experience from leading positions in life science. Edberg’s previous positions include Managing director and Vice President of Mylan AB, the Nordic countries, CEO for LFF Service AB, the Swedish Pharmaceutical Insurance Association and NM Pharma AB and senior positions from LinkMed AB (Allenex), Pfizer, Pharmacia, Bactiguard and Cilag (Johnson & Johnson) AB. Her previous board assignments include chairman of Immunicum AB (publ), Health Solutions AB, BioResonator Good Eye AB and BioMatCell – Vinn Excellence Center of Biomaterials and Cell Therapy. Current assignments include Chairman at Likvor AB and Ambulanssjukvården i Storstockholm AB (AISAB), board member of TSS AB, CAMP (a Swedish Consortium Center for Advanced Medical Products) and member of CellProtect AB. Agneta Edberg has a degree in health economics from Stockholm School of Economics as well as a biomedical education from Sundsvall University.

Holdings: 157,257 shares

Warrant TO5: 195,360

Independent in relation to the Company and its management and the Company´s major shareholders.

Christina Herder

Member of the board since 2017

Christina Herder has 25 years of experience in early phase drug development and business development in the pharmaceutical industry. Her previous assignments include several senior roles in among other Swedish Orphan Biovitrum AB (Sobi) and Biovitrum. Christina currently holds the position as Executive Vice President, Strategic Business Development at Medivir AB, (listed on Nasdaq, Stockholm). Previous to that Christina was the CEO of Modus Therapeutics, a Swedish drug development company. Since 2015 she has been a member of the Board of PCI Biotech Holding ASA (listed on Oslo Axess). Christina Herder holds a doctorate from the Royal Institute of Technology in Stockholm and an Executive MBA from Stockholm University.

Holdings: 62,718 shares

Warrant TO5: 99,000

Independent in relation to the Company and its management and the Company´s major shareholders.

Sharon Longhurst

Member of the board since 2020

Sharon Longhurst has 20 years of experience in manufacturing and quality control of various biological pharmaceuticals, both as head of operations and as consultant. Her career includes six years as a reviewer at the UK Medicines and Healthcare products Regulatory Agency, and positions of responsibility for the quality assessment of chemistry, manufacturing and control (CMC) in EU applications for the approval of cell and gene therapies. Her subsequent positions included working as a consultant for producing biological pharmaceuticals, and represented the UK as deputy chair of the EMA Gene Therapy Working Party programme for the European Medicines Agency. Sharon Longhurst has a background in virology and has been working as head of CMC at Immunicum AB (publ) for the last four years.

Holdings: 92,400 shares

Warrant TO5: 126,000

Independent in relation to the Company and its management and the Company´s major shareholders.

Auditor

Maria Ekelund

Auditor

At the 2019 Annual General Meeting, the accounting firm Deloitte AB, was reelected to be the company’s auditor. Maria Ekelund was appointed as lead auditor. The accounting firm Deloitte AB and the main responsible auditor Maria Ekelund do not perform any services that could bring their independence into question.